| P2093 | author name string | Jae-Ho Cheong | |
| | Min-Kyue Shin | |
| P2860 | cites work | Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer | Q46894958 |
| | Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres | Q47222664 |
| | Survival of cancer stem-like cells under metabolic stress via CaMK2α-mediated upregulation of sarco/endoplasmic reticulum calcium ATPase expression | Q47253196 |
| | Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development | Q47285805 |
| | PGC1α: Friend or Foe in Cancer? | Q47844268 |
| | Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. | Q47914208 |
| | Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study | Q48394963 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models | Q22252348 |
| | Regulation and function of AMPK in physiology and diseases | Q26740291 |
| | Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer | Q26747750 |
| | Repurposing metformin for cancer treatment: current clinical studies | Q26752651 |
| | Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics | Q26771751 |
| | PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion | Q27324467 |
| | Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies | Q28081491 |
| | Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxel | Q28533247 |
| | Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells | Q28533608 |
| | Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures | Q28550603 |
| | Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). | Q30353578 |
| | Catabolic metabolism during cancer EMT. | Q38336993 |
| | The inhibition of migration and invasion of cancer cells by graphene via the impairment of mitochondrial respiration. | Q38444045 |
| | Tumorigenesis: it takes a village | Q38544200 |
| | Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? | Q38578526 |
| | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. | Q38659483 |
| | A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors | Q38712122 |
| | NDRG2 overexpression suppresses hepatoma cells survival during metabolic stress through disturbing the activation of fatty acid oxidation | Q38722276 |
| | Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. | Q38752730 |
| | Mitochondrial elongation-mediated glucose metabolism reprogramming is essential for tumour cell survival during energy stress | Q38823235 |
| | Cancer metabolism: a therapeutic perspective | Q38824435 |
| | The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications | Q38838561 |
| | Hallmarks of cancer stem cell metabolism. | Q38842974 |
| | Precancer Atlas to Drive Precision Prevention Trials. | Q38857539 |
| | Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells | Q38862527 |
| | Mitochondrial free fatty acid β-oxidation supports oxidative phosphorylation and proliferation in cancer cells. | Q38864224 |
| | Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells | Q38910917 |
| | Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. | Q38922496 |
| | Lipid catabolism via CPT1 as a therapeutic target for prostate cancer | Q38966211 |
| | The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation | Q38996807 |
| | Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. | Q38996812 |
| | Mitochondrial dynamics as regulators of cancer biology | Q39084933 |
| | Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance | Q39088754 |
| | Understanding the Intersections between Metabolism and Cancer Biology | Q39130440 |
| | PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. | Q39132660 |
| | Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis | Q39181566 |
| | Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells | Q40067927 |
| | Regulation of cellular energy metabolism | Q40115793 |
| | Metabolic shifts in residual breast cancer drive tumor recurrence | Q40201374 |
| | Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors | Q40969918 |
| | Mitochondria on the move: emerging paradigms of organelle trafficking in tumour plasticity and metastasis | Q41193216 |
| | Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells | Q41458947 |
| | A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds | Q42269519 |
| | Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A Novel Mechanism Linking Obesity and Cancer. | Q42810435 |
| | A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance | Q43195305 |
| | Regulation of SIRT3 signal related metabolic reprogramming in gastric cancer by Helicobacter pylori oncoprotein CagA. | Q43743808 |
| | The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation | Q46418283 |
| | Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death | Q46714640 |
| | Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy | Q46859787 |
| | Knockdown of TWIST1 enhances arsenic trioxide- and ionizing radiation-induced cell death in lung cancer cells by promoting mitochondrial dysfunction | Q46892039 |
| | Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. | Q48544710 |
| | Adipocyte biology in breast cancer: From silent bystander to active facilitator. | Q49632784 |
| | The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation | Q49678727 |
| | Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. | Q49923401 |
| | Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer | Q50279163 |
| | In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. | Q51266975 |
| | The carnitine system and cancer metabolic plasticity. | Q51769132 |
| | Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. | Q52715643 |
| | Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. | Q52726871 |
| | Implications of oncocytic change in papillary thyroid cancer. | Q53093174 |
| | Mitochondria and Cancer. | Q53198693 |
| | Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. | Q53641389 |
| | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. | Q54938715 |
| | The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells. | Q55004493 |
| | Anticancer Properties of Fenofibrate: A Repurposing Use. | Q55021652 |
| | Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. | Q55333214 |
| | Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis | Q57618013 |
| | Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma | Q57794783 |
| | Mitochondrial metabolism and cancer | Q57842307 |
| | Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer | Q58696780 |
| | The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells | Q59529106 |
| | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT | Q60683128 |
| | Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases. | Q64896684 |
| | Targeting leukemia's "fatty tooth" | Q86496846 |
| | An inhibitor of oxidative phosphorylation exploits cancer vulnerability | Q89070252 |
| | Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism | Q89242498 |
| | The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress | Q89460819 |
| | When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance | Q89573138 |
| | Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas | Q30383438 |
| | Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity | Q30833290 |
| | Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. | Q34005286 |
| | Metabolic differences in breast cancer stem cells and differentiated progeny | Q34039960 |
| | Growth inhibition of ovarian tumor-initiating cells by niclosamide. | Q34265703 |
| | Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. | Q34412152 |
| | Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission | Q34611836 |
| | Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition | Q34956497 |
| | Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. | Q35084900 |
| | Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function | Q35223050 |
| | Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models | Q35613319 |
| | Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease | Q35741510 |
| | Regulators of mitochondrial dynamics in cancer | Q35929111 |
| | Adaptive mitochondrial reprogramming and resistance to PI3K therapy. | Q36047440 |
| | Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. | Q36191986 |
| | Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells | Q36213711 |
| | Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition | Q36293834 |
| | The Emerging Hallmarks of Cancer Metabolism | Q36468964 |
| | Metabolic Heterogeneity in Human Lung Tumors. | Q36578111 |
| | Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. | Q36793719 |
| | MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells | Q36950291 |
| | Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer | Q36967938 |
| | Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells | Q37059785 |
| | Cancer metabolism: fatty acid oxidation in the limelight | Q37155867 |
| | Aldehyde dehydrogenase is used by cancer cells for energy metabolism | Q37463894 |
| | Integrated omics-analysis reveals Wnt-mediated NAD+ metabolic reprogramming in cancer stem-like cells | Q37565536 |
| | Phospholipase D1-regulated autophagy supplies free fatty acids to counter nutrient stress in cancer cells | Q37603284 |
| | Changing appetites: the adaptive advantages of fuel choice | Q37624803 |
| | In vivo Reprogramming of Cancer Metabolism by MYC. | Q37746816 |
| | Oncocytic mania: a review of oncocytic lesions throughout the body | Q37837353 |
| | Profiling metabolic networks to study cancer metabolism | Q38064557 |
| | Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis | Q38167545 |
| | Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy | Q38301212 |
| | Metabolism in embryonic and cancer stemness. | Q38322832 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| | neoplastic stem cells | Q1638475 |
| | tumor microenvironment | Q1786433 |
| | energy metabolism | Q30225378 |
| P304 | page(s) | 113-127 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Archives of Pharmacal Research | Q13557312 |
| P1476 | title | Mitochondria-centric bioenergetic characteristics in cancer stem-like cells | |
| P478 | volume | 42 | |